Clinical Trials Logo

T-Cell Lymphoma Refractory clinical trials

View clinical trials related to T-Cell Lymphoma Refractory.

Filter by:
  • None
  • Page 1

NCT ID: NCT03552692 Terminated - Clinical trials for T-Cell Lymphoma Relapsed

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Start date: September 25, 2018
Phase: Phase 2
Study type: Interventional

The FIL_VERT study is a phase II, open label, multicenter clinical trial. The primary of objective of the Study is to evaluate the efficacy of Venetoclax ABT-199/GDC-0199) in terms of overall response rate (ORR) in patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal T-cell lymphomas of T-follicular helper origin (TFH)

NCT ID: NCT03046953 Completed - Clinical trials for T-Cell Lymphoma Relapsed

Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma

AVAIL-T
Start date: November 14, 2017
Phase: Phase 2
Study type: Interventional

The AVAIL-T trial is a trial to find out how effective avelumab is at treating patients with primary T-cell lymphoma that is refratory to or has relapsed following initial treatment.